Wikipedia -WSS

Wikipedia

author：explore 2025-09-10 05:03:28 - browse：22521

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Fetal cell organoids grown from amniotic fluid, study finds

WSS

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Lawsuit challenges CMS nursing home minimum staffing rule

Immune cells and nerve overgrowth may explain recurring UTI pain

Why we need mandatory labeling of GMO products

Stem cell biologist probes earliest stages of human development

Stem cell biologist probes earliest stages of human development

Wikipedia

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Guardant Health colon cancer test endorsed by FDA advisory panel

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

$1 billion proposal to grow Boston, Massachusetts biotech

United colonoscopy coverage change 'may cost lives,' doctors say

He's 19 months old and has one of the world’s rarest diseases

Trump demands the U.S. pay no more for drugs than other countries … again

Pregnant women don't need prenatal multivitamins, study concludes

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Fetal cell organoids grown from amniotic fluid, study finds

knowledge

Achieving telehealth equity for people with hearing loss

Stem cell biologist probes earliest stages of human development

Readout Newsletter: BridgeBio, Akero, and human embryo models

Should insurance cover cosmetic surgery?

Immune cells and nerve overgrowth may explain recurring UTI pain

U.S. death rates show how politics are affecting public health

focus

entertainment

entertainment

knowledge